Stalled $3B Dementia Research Fund Faces Court in Texas 2026

News Desk
Stalled $3B Dementia Research Fund Faces Court in Texas 2026
Google Map,Camilo Diaz Jr. for The Texas Tribune

Key Points:

  • One year after 70% of Texas voters approved the $3 billion Dementia Prevention and Research Institute of Texas (DPRIT), the fund remains inactive due to a legal challenge over voting machine accuracy testing.
  • The lawsuit, filed by self-represented plaintiffs Shannon Huggins of Snook and Jose Silvester of Schertz, was dismissed by a Travis County judge in February 2026 but has sat pending before the 15th Court of Appeals ever since.
  • Incoming Democratic leadership in Texas brings fresh uncertainty alongside optimism from advocates, as Governor-elect Gina Hinojosa, Lieutenant Governor-elect Vikki Goodwin, and House speaker candidate Rep. Senfronia Thompson previously supported the measure.
  • Republican State Rep. Brian Harrison of Midlothian recently filed House Bill 822 seeking to ask voters to abolish DPRIT and redirect the $3 billion toward property tax relief.
  • Roughly 459,000 Texans over age 65 live with Alzheimer’s disease, supported by over one million unpaid caregivers, while universities like Rice University and the University of Texas at Dallas have already prepared research infrastructure for the stalled grants.
  • In September 2026, the Alzheimer’s Association and the American Heart Association filed a joint friend-of-the-court brief urging appellate judges to affirm the lower court’s dismissal.
  • Outgoing Republican Lt. Gov. Dan Patrick, who originally championed the initiative in late 2024 before losing his re-election bid in November 2026, has declined repeated media requests to comment on the fund’s current stalemate.

TEXAS (Edition America) — November 17, 2026 — A landmark $3 billion state research fund designed to combat Alzheimer’s, Parkinson’s, and other neurodegenerative diseases remains completely stalled one full year after receiving overwhelming approval from 70% of Texas voters. As reported by Terri Langford of The Texas Tribune, the Dementia Prevention and Research Institute of Texas (DPRIT) has been held up in the 15th Court of Appeals by a voter lawsuit challenging ballot-tabulating machines, leaving patients, caregivers, and university researchers in limbo as a newly elected Democratic administration prepares to take office alongside fresh legislative efforts to repeal the program.

Why Is Texas’s $3 Billion Dementia Research Fund Still Stalled?

Originally championed in late 2024 by outgoing Republican Lieutenant Governor Dan Patrick, the proposal to establish a $3 billion dementia research endeavor sailed through both chambers of the Texas Legislature before securing 70% voter approval in November 2025. As reported by Terri Langford of The Texas Tribune, Lt. Gov. Dan Patrick stated when launching the concept in late 2024 that “Dementia, and especially Alzheimer’s … is a heartbreaking and devastating disease.” He added, “Just as we are leading on cancer research, Texas can be a world leader in combating dementia, finding treatment and, one day, a cure.”

Despite the decisive ballot victory, DPRIT has failed to launch or distribute grants from the $3 billion sitting at the Texas Comptroller’s office. The delay stems from a lawsuit filed in late 2025 by two Texas voters—Shannon Huggins of Snook and Jose Silvester of Schertz—who are representing themselves in court. The plaintiffs allege that the machines utilized to tabulate election results were not properly tested for accuracy, thereby invalidating ballots counted on them.

Although a Travis County judge dismissed the lawsuit in February 2026, the plaintiffs appealed the ruling to Texas’s newest civil court, the 15th Court of Appeals, where the docket has remained unresolved. As noted by Terri Langford of The Texas Tribune, the court’s three Republican judges are scheduled to vacate their seats in January 2027 to make way for three newly elected Democrats, leaving the outgoing jurists a narrow window either to rule on the appeal or pass the matter to the incoming bench. Both Shannon Huggins and Jose Silvester have previously declined to discuss their litigation and could not be reached for comment. Meanwhile, Lt. Gov. Dan Patrick—who was defeated in the November 2026 election—has remained silent on the issue since the suit was initially filed, declining repeated interview requests from The Texas Tribune over the past year.

How Will Incoming Democratic Leadership and New Bills Affect DPRIT?

The political landscape surrounding the $3 billion fund has shifted dramatically following the November 2026 elections, which swept Democrats into key statewide offices and legislative control. With incoming lawmakers focused on major policy priorities such as Medicaid expansion, voting rights, and data center regulations, questions have emerged regarding whether the new leadership will actively defend the stalled dementia institute or seek alternative uses for the allocated funds.

However, patient advocacy leaders expressed confidence that the program’s bipartisan roots will ensure its survival. As reported by Terri Langford of The Texas Tribune, Laura Cilmi, spokesperson for the Alzheimer’s Association, stated that “Last week’s results are a reason for confidence, not worry.” Pointing out that Governor-elect Gina Hinojosa and Lieutenant Governor-elect Vikki Goodwin co-sponsored the original enabling legislation, while House speaker favorite Representative Senfronia Thompson served as its lead sponsor, Laura Cilmi added, “DPRIT’s support was never tied to one office or one party. That bipartisan foundation carries into the next Legislature regardless of who holds which office.”

Simultaneously, opposition persists within the legislature. Republican State Representative Brian Harrison of Midlothian, an early critic of the fund, filed House Bill 822 seeking a new ballot measure to abolish DPRIT and redirect the $3 billion toward property tax relief. While The Texas Tribune was unable to reach Rep. Brian Harrison for immediate comment on his filing, Terri Langford referenced his previous remarks from the House floor last year, where Rep. Brian Harrison stated, “I would love to find a cure for dementia … but I don’t know what part of stop growing government and give people back their money this body clearly does not understand.” Addressing the legislative pushback, Laura Cilmi noted, “Rep. Harrison was in the minority that didn’t support DPRIT when it passed the Legislature and again when Texas voters were asked to approve the funding.”

What Is the Impact of the Delay on Texas Patients, Families, and Researchers?

The prolonged administrative freeze has weighed heavily on Texas’s medical community, academic institutions, and hundreds of thousands of affected residents. Currently, approximately 459,000 Texans over the age of 65 are living with Alzheimer’s disease, while more than one million residents provide unpaid caregiving support across the state.

Anticipating a major influx of state research capital over the next decade, academic centers mobilized prior to the program’s passage. Rice University established dedicated brain research departments, while the University of Texas at Dallas allocated internal seed funding to help faculty prepare grant applications for DPRIT. In September 2026, the Alzheimer’s Association and the American Heart Association jointly submitted an amicus curiae brief urging appellate judges to uphold the lower court’s dismissal. As cited by Terri Langford of The Texas Tribune, the joint legal brief stated, “At its core, DPRIT seeks to address the growing public health crisis in Texas related to dementia.” It further emphasized, “Texas created DPRIT at a moment when the need for dementia research is urgent and the opportunities for scientific advancement are significant. Continued delay today postpones scientific progress tomorrow.”

For individual patients navigating the disease, the stalled timeline carries personal urgency. Retired Dallas attorney Luke Davis, 72, who was diagnosed with early-stage Alzheimer’s three years ago in 2023, described the voter-approved fund as an obvious progression following Texas’s creation of a similar cancer research institute in 2007. Following his diagnosis, Luke Davis and his wife, Paula, immersed themselves in clinical research, participated in Alzheimer’s Association educational programs, and traveled to Washington to lobby lawmakers.

Luke Davis began treatment with Leqembi—a medication granted accelerated approval by the U.S. Food and Drug Administration in 2023 to slow Alzheimer’s progression by targeting amyloid brain plaque—and has recorded a two-thirds reduction in brain plaque over 18 months. Speaking to Terri Langford of The Texas Tribune, Luke Davis stated, “Our mantra though, from the very beginning, was we’re going to live with this, not die from it.” He added, “And we’re going to do what we can while we can.” Describing his weekly routine of checking the appellate court docket online for updates, Luke Davis noted, “Once a week we’ll pull it (case) up on the appeals website to see, has anything happened?” Reflecting on the self-represented litigants holding up the fund, he concluded, “It’s probably a good thing Paula does not meet those plaintiffs. I think there’s a lot of people who feel that way.”

Background of the Particular Development

The Dementia Prevention and Research Institute of Texas (DPRIT) was modeled directly after the Cancer Prevention and Research Institute of Texas (CPRIT), a multi-billion-dollar state funding agency approved by Texas voters in 2007 that transformed Texas into a leading hub for oncology research and clinical trials. Recognizing the demographic and fiscal toll of neurodegenerative disorders on an aging population, state leaders proposed replicating that institutional framework for brain health. However, the post-election litigation challenging electronic voting machine certification reflects a broader pattern of election-related legal challenges across Texas in recent years, which have increasingly been utilized by individual litigants to delay the implementation of constitutional amendments and voter-approved bond or funding measures.

Prediction

This unresolved legal and political standoff could significantly affect academic research institutions, healthcare providers, and families managing neurodegenerative conditions across Texas over the coming year. For the particular audience of biomedical researchers, university administrators, and clinical trial teams at institutions such as Rice University and the University of Texas at Dallas, prolonged appellate inaction risks stalling laboratory recruitment, delaying grant cycles, and ceding competitive scientific talent to rival research states. Conversely, if either the outgoing judges on the 15th Court of Appeals or the incoming Democratic bench in January 2027 swiftly affirms the lawsuit’s dismissal, the immediate release of the $3 billion allocation—backed by incoming Democratic leaders who originally co-sponsored the legislation—could rapidly catalyze large-scale clinical research and therapeutic development across Texas throughout 2027.